AR022937A1 - Celulas mamiferas conjugadas con haptenos y metodos para su constitucion y uso - Google Patents
Celulas mamiferas conjugadas con haptenos y metodos para su constitucion y usoInfo
- Publication number
- AR022937A1 AR022937A1 ARP000101145A ARP000101145A AR022937A1 AR 022937 A1 AR022937 A1 AR 022937A1 AR P000101145 A ARP000101145 A AR P000101145A AR P000101145 A ARP000101145 A AR P000101145A AR 022937 A1 AR022937 A1 AR 022937A1
- Authority
- AR
- Argentina
- Prior art keywords
- tumor
- cells
- mammalian
- conjugated
- hapten
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 210000004216 mammary stem cell Anatomy 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 8
- 210000004027 cell Anatomy 0.000 abstract 6
- 238000011282 treatment Methods 0.000 abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 239000000284 extract Substances 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 210000004881 tumor cell Anatomy 0.000 abstract 3
- 230000012010 growth Effects 0.000 abstract 2
- 210000004962 mammalian cell Anatomy 0.000 abstract 2
- 230000004044 response Effects 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010054094 Tumour necrosis Diseases 0.000 abstract 1
- 230000003698 anagen phase Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 230000000495 immunoinflammatory effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000008595 infiltration Effects 0.000 abstract 1
- 238000001764 infiltration Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000005951 type IV hypersensitivity Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a células mamíferas conjugadas con hapteno y a métodos para la constitucion y el uso de las mismas. La conjugacion de células con unhapteno es una forma eficaz de prevenir que las células crezcan y puede ser utilizada en lugarde tratamientos convencionales, por ejemplo, la irradiacion. Porlo tanto, la presente se relaciona con células mamíferas en general, por ejemplo, células humanas, que se encuentran en estado de crecimiento nulo; serelaciona también con un métodomedi ante el cual se ponen las células en una fase de crecimiento nulo al conjugarlas con un hapteno. La presente se refiereademás a composiciones que contienen células tumorales modificadas con un hapteno y extractos y métodos para el tratamientodel cán cer mediante laadministracion de una cantidad terapéuticamente efectiva de una composicion que contiene una célula tumoral o un extracto de célula tumoral a una persona quenecesita dicho tratamiento. Las células y los extractos tumorales dela presen te y sus composiciones son capaces de liberar linfocitos T que poseen propiedadde infiltrarse en el tumor del mamífero, generar una respuesta inmunoinflamatoria al tumor del mamífero y generar una respuesta de hipersensibilidad detiporetardada al tu mor del mamífero y/o estimular los linfocitos T in vitro. La presente también se relaciona con un programa de vacunacion eficaz que tiene por lomenos una de las siguientes consecuencias: necrosis tumoral, regresion tumoral,inflamacion tumoral, infil tracion tumoral de linfocitos T activos, respuesta desensibilidad de tipo retardada, y prolongacion del tiempo de vida del paciente. Además, la presente se relaciona con un método mejorado, simplificado yeconomico depreparacion de células conjugadas con haptenos que deben ser administradas en forma de vacuna. En dicho método, se elimina el paso de tratamientode las células (por irradiacion, por ejemplo) a fin de ponerlas en un estado de crecimiento nulo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12467299P | 1999-03-16 | 1999-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR022937A1 true AR022937A1 (es) | 2002-09-04 |
Family
ID=22416199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000101145A AR022937A1 (es) | 1999-03-16 | 2000-03-15 | Celulas mamiferas conjugadas con haptenos y metodos para su constitucion y uso |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6403104B1 (es) |
| EP (2) | EP1723963A3 (es) |
| AR (1) | AR022937A1 (es) |
| AT (1) | ATE341338T1 (es) |
| AU (1) | AU757980B2 (es) |
| CA (1) | CA2367922A1 (es) |
| DE (1) | DE60031100T2 (es) |
| ES (1) | ES2273680T3 (es) |
| WO (1) | WO2000057911A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1723963A3 (en) * | 1999-03-16 | 2008-05-07 | Thomas Jefferson University | Hapten-conjugated tumour cells |
| US7297330B2 (en) * | 2000-02-04 | 2007-11-20 | Thomas Jefferson University | Low dose haptenized tumor cell and tumor cell extract immunotherapy |
| US20030165518A1 (en) * | 2002-02-01 | 2003-09-04 | Thomas Jefferson University | Mixed haptenized tumor cells and extracts and methods of treating or screening for cancer |
| EP1551225A4 (en) * | 2002-06-10 | 2011-05-25 | Avax Technologies Inc | KRYOKONSERVATION OF HAPEN-MODIFIED TUMOR CELLS |
| US7674456B2 (en) * | 2004-06-14 | 2010-03-09 | Charles Wiseman | Breast cancer cell lines and uses thereof |
| US8257715B1 (en) | 2004-08-26 | 2012-09-04 | University Of Notre Dame | Tissue vaccines and uses thereof |
| CA2593191A1 (en) * | 2005-01-14 | 2006-07-20 | Avax Technologies, Inc. | Method for producing a vaccine for the treatment of cancer |
| US8778362B2 (en) | 2005-10-27 | 2014-07-15 | University Of Notre Dame | Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof |
| US8802113B2 (en) * | 2005-10-27 | 2014-08-12 | University Of Notre Dame | Extracellular matrix cancer vaccine adjuvant |
| US8778360B2 (en) * | 2005-10-27 | 2014-07-15 | University Of Notre Dame | Extracellular matrix cancer vaccine adjuvant |
| US9308252B2 (en) * | 2005-10-27 | 2016-04-12 | Cook Biotech, Inc. | Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins |
| US9283266B2 (en) * | 2008-02-28 | 2016-03-15 | University Of Notre Dame | Metastasis inhibition preparations and methods |
| US8846059B2 (en) | 2009-12-08 | 2014-09-30 | University Of Notre Dame | Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer |
| US20110150934A1 (en) * | 2009-12-18 | 2011-06-23 | University Of Notre Dame | Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer |
| WO2014120941A1 (en) * | 2013-02-01 | 2014-08-07 | University Of Iowa Research Foundation | Tumor vaccines and methods of use thereof |
| US20210100896A1 (en) * | 2017-04-05 | 2021-04-08 | University Of Miami | Methods and compositions for stimulating the immune system |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5290557A (en) | 1992-07-16 | 1994-03-01 | W. Neudorff Gmbh Kg | Saponin containing anti-feedant and molluscicide for terrestrial mollusc control |
| IL122455A0 (en) * | 1995-06-07 | 1998-06-15 | Univ Jefferson | Hapten modified tumor cell extract and methods of treating or screening for cancer |
| NZ330995A (en) | 1996-10-04 | 2000-12-22 | Univ Jefferson | Generation of T cells mediating an immune response and use for treating cancer |
| WO1999052546A2 (en) | 1998-04-09 | 1999-10-21 | Thomas Jefferson University | A method of inducing an anti-tumor response against a lung metastasis in a melanoma patient |
| EP1723963A3 (en) * | 1999-03-16 | 2008-05-07 | Thomas Jefferson University | Hapten-conjugated tumour cells |
-
2000
- 2000-03-15 EP EP06008353A patent/EP1723963A3/en not_active Withdrawn
- 2000-03-15 DE DE60031100T patent/DE60031100T2/de not_active Expired - Fee Related
- 2000-03-15 AR ARP000101145A patent/AR022937A1/es unknown
- 2000-03-15 EP EP00919412A patent/EP1162996B1/en not_active Expired - Lifetime
- 2000-03-15 AU AU40106/00A patent/AU757980B2/en not_active Ceased
- 2000-03-15 ES ES00919412T patent/ES2273680T3/es not_active Expired - Lifetime
- 2000-03-15 AT AT00919412T patent/ATE341338T1/de not_active IP Right Cessation
- 2000-03-15 CA CA002367922A patent/CA2367922A1/en not_active Abandoned
- 2000-03-15 WO PCT/US2000/006785 patent/WO2000057911A2/en active IP Right Grant
- 2000-03-16 US US09/526,395 patent/US6403104B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2273680T3 (es) | 2007-05-16 |
| EP1723963A3 (en) | 2008-05-07 |
| WO2000057911A2 (en) | 2000-10-05 |
| ATE341338T1 (de) | 2006-10-15 |
| US6403104B1 (en) | 2002-06-11 |
| CA2367922A1 (en) | 2000-10-05 |
| EP1162996A2 (en) | 2001-12-19 |
| AU4010600A (en) | 2000-10-16 |
| EP1723963A2 (en) | 2006-11-22 |
| EP1162996B1 (en) | 2006-10-04 |
| AU757980B2 (en) | 2003-03-13 |
| DE60031100T2 (de) | 2007-03-08 |
| DE60031100D1 (de) | 2006-11-16 |
| WO2000057911A3 (en) | 2001-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR022937A1 (es) | Celulas mamiferas conjugadas con haptenos y metodos para su constitucion y uso | |
| Siegler et al. | Off-the-shelf CAR-NK cells for cancer immunotherapy | |
| Wen et al. | Supramolecular peptide vaccines: tuning adaptive immunity | |
| Chang et al. | Supramolecular immunotherapy of cancer based on the self‐assembling peptide design | |
| ES2843509T3 (es) | Vacunas con mayor densidad de antígeno carbohidratado y nuevo adyuvante de saponina | |
| ES2190472T3 (es) | Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno. | |
| TR201903587T4 (tr) | Telomeraz aktivitesinin artırılması için bileşimler. | |
| JP2010516259A5 (es) | ||
| Farran et al. | Folate-targeted immunotherapies: Passive and active strategies for cancer | |
| AR016254A1 (es) | Una composicion de celulas de tumor modificadas con un hapteno o extracto de celulas tumorales y uso de la misma en la elaboracion de un medicamento. | |
| AR068984A1 (es) | Proceso para la obtencion de celulas presentadoras de antigenos activados, utiles en las terapias contra el cancer y enfermedades relacionadas del sistema inmunologico | |
| ATE418344T1 (de) | Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten | |
| RU2011108486A (ru) | ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ПЕПТИДА Wnt5-a ДЛЯ ЛЕЧЕНИЯ МЕЛАНОМЫ И РАКА ЖЕЛУДКА | |
| AR033403A1 (es) | Uso de reovirus para la fabricacion de un medicamento para reducir una masa tumoral solida. | |
| DK0889969T3 (da) | Rekombinante adenovirale til genterapi af humane tumorer | |
| JP2009530359A (ja) | 腫瘍成長の阻害 | |
| CA2354045A1 (en) | New cancer treatments | |
| Faries | Intralesional immunotherapy for metastatic melanoma: the oldest and newest treatment in oncology | |
| JPH07101875A (ja) | 膀胱ガンに対して高い抗腫瘍活性を有するカサガイヘモシアニン | |
| ES2329529T3 (es) | Formulaciones terapeuticas que contienen veneno de serpiente y/o de insecto para la profilaxis y la terapia del neoplasma. | |
| Robinson et al. | 6-mercaptopurine in immunological responsiveness | |
| US20220133884A1 (en) | Compounds useful as adjuvants | |
| AR006214A1 (es) | Un metodo para movilizar celulas mediante el tratamiento con hialuronan (ha) | |
| ES2898626T3 (es) | Vacuna terapéutica contra el cáncer a base de proteínas de estrés inmunogénicas | |
| BR0303362A (pt) | Composição e método para melhorar uma resposta imune em um animal, método para distribuir uma proteìna de carga em uma célula de animal, célula viva geneticamente modificada, e, método para a construção de uma proteìna de fusão para melhorar a resposta imune em um animal |